^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BP1200

i
Other names: BP1200
Associations
Trials
Company:
BrightPath Biotherap
Drug class:
CD73 inhibitor
Associations
Trials
over2years
A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy (AACR 2022)
The novel anti-human CD73 antibody, BP1200, ameliorates immunosuppressive TME caused by adenosine and enhances antitumor immune responses. The combination of BP1200 and immune-checkpoint inhibitors for cancer treatment will be a promising therapeutic option in clinical practice.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
NT5E (5'-Nucleotidase Ecto)
|
CD73 expression
|
BP1200